Skip to main content

Table 4 Mazzotti reactions after OCP-patch and LTS-2 patch application

From: Diagnosis of O. volvulus infection via skin exposure to diethylcarbamazine: clinical evaluation of a transdermal delivery technology-based patch

Mazzotti reactions After OCP-patch After LTS-2 patch
Itching at patch application site: n (%)* 19 (63.3 %) at OCP-patch site 6 (20.0 %) at LTS-2 patch site
   3 (10.0 %) at OCP-patch siteb
 Start (hrs after patch application)a Mean ± SD 12.6 ± 13.4 6.9 ± 6.9 at LTS-2 patch site
 Start (hrs after patch application)a Range (Median) 0.8–52.0 (8.2) 1.5–19.4 (4.1) at LTS-2 patch site
   0.1, 0.5, 4.1 + 36.1 – at OCP-patch
 Duration (hrs): Mean ± SDa, ** 8.9 ± 11.8 1.0 ± 2.5 at LTS2 patch
 Duration (hrs): Range (Median) 0–56 (7.63) 0–8.9 (0) – at LTS–2 patch
 Duration (hrs)   1.1, 4, 6 + 12 – at OCP-patch
Itching involving the whole body: n (%) 5 (16.7) 2 (6.7 %)
 Start (hrs after patch application) 4.1, 28.1, 51.9, 36.4, 4.3 5.7, 13.2
 Duration (hrs) 7.9, 8.0, 8.2, 23.8, 55.9 6.3, 15.0
Itching at back 1 (3.3 %) 0
Other clinical Mazzotti reactions   
 Burning sensation at patch sitec 2 (6.7 %) 0
 Pain at patch site 1 (3.3 %) 0
Haematological/biochemical reactions   
 Leucocytosis with increase in peripheral granulocytes 4 (13.3) 6 (20.0 %)
 Increase in AST 3 (10 %)d 0
 Increase in ALT 3 (10 %)d 4 (13.3 %) + 2 (6.7 %d)
 Increase in ALP 0 2 (6.7 %)
  1. * p = 0.0015, ** p = 0.0014, adescriptive statistics calculated across subjects with itching, bincludes 1 subject who had no itching at the OCP-patch site after the OCP-patch application, cdescribed by the participants as ‘pepper on the skin’, duration 3.3 and 6.4 h, resp. dElevations persisted into period after LTS-2 application and in 2 participants ALT elevation increased from grade 1 after OCP-patch application to grade 2 after LTS-2 patch application